Mandate

Vinge acts for Medivir in connection with public offer

April 13, 2011

Vinge acts for Medivir in connection with the public offer for BioPhausia AB (publ) (NASDAQ OMX Stockholm) has announced a public offer for BioPhausia AB (publ) (NASDAQ OMX Stockholm). Vinge acts for Medivir.

Vinge’s team is headed by capital markets and public M&A partner Erik Sjöman and includes, among others, Christian Lindhé, Emil Hedberg, Jakob Warren and Markus Larsson. Göran Nyström (public M&A), Kristian Hugmark and Hanna Danwall (competition law) and Mattias Schömer and Maria Doeser (tax) are also on the team.

Related

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025

Vinge is advising on the establishment of Ballista Capital

Ballista Capital held its final closing on 9 June 2025. The investor base primarily comprises family offices and investors with strong ties to northern Sweden.
July 07, 2025